Konrad Talbot

Konrad Talbot, PhD is an Associate Professor at Loma Linda University School of Medicine with dual appointments in both the Pharmacology Division and Pathology Division. His research spans neuroscience, neuropharmacology, and the intersection of metabolic disorders with neurodegenerative diseases.

Dr. Talbot's primary research interests focus on brain insulin resistance in Alzheimer's disease and other neurodegenerative conditions. His extensive work has explored the therapeutic potential of incretin receptor agonists (such as GLP-1 analogs) for treating Alzheimer's and Parkinson's diseases. He has made significant contributions to understanding how these diabetes medications cross the blood-brain barrier and potentially ameliorate cognitive decline associated with insulin resistance in the brain.

Another major research focus has been on schizophrenia pathophysiology, particularly investigating the role of dysbindin-1 in synaptic function and how its disruption leads to cognitive deficits characteristic of schizophrenia. His work has connected molecular abnormalities in dysbindin-1 with NMDA receptor hypofunction and working memory impairments.

Analysis of Dr. Talbot's recent publications (2022-2024) reveals a consistent trajectory in two main research streams: neurodegenerative diseases with emphasis on brain insulin resistance and incretin-based therapeutics, and schizophrenia research focusing on dysbindin-1 and synaptic protein networks. His work shows progression from basic molecular mechanisms toward potential clinical applications, with increasing emphasis on detailed pharmacokinetic studies of incretin receptor agonists in the brain.

Dr. Talbot's research has been published in high-impact journals including Nature Medicine, Journal of Clinical Investigation, Alzheimer's and Dementia, and Molecular Psychiatry. His work bridges basic neuroscience with translational applications, particularly in repurposing diabetes medications for neurodegenerative conditions.